Changing Lives, One Step at a Time: HyProCure® Marks 8 Years

Oct. 4, 2012 - PRLog -- Macomb, MI – Over the past eight years, HyProCure^®, a Type II Extra-Osseous TaloTarsal Stabilization (EOTTS) device, has become the leading solution for patients suffering with the symptoms and secondary conditions resulting from partial talotarsal dislocation. TaloTarsal Displacement is a foot imbalance that throws both the foot and the entire body out of alignment. It affects people of all ages and is often the direct or contributing cause of overpronation, bunions, plantar fasciitis, knee pain, hip pain, back pain, and even problems in the neck and shoulders.

This pioneering device is placed deep into the canalis portion of the sinus tarsi, reestablishing the normal pivot over which the talus (ankle bone) glides, thereby properly realigning the foot and ankle bones and restoring normal function. Via a minimally invasive procedure, the HyProCure^® device instantly stabilizes the hindfoot bones, stopping the continued trauma to the foot and body, and even possibly leading to the reversal of associated conditions. HyProCure^® represents a real solution for talotarsal displacement and its devastating effects throughout the body.

HyProCure^® was invented by Michael E. Graham, DPM, FACFAS, FAENS. In his practice, Dr. Graham specialized in the correction of foot and ankle instability. Recognizing the significant limitations of the sinus tarsi implants on the market, he developed HyProCure^®. The device received FDA approval on September 16, 2004 and the first HyProCure^® placement took place on September 22, 2004. As more and more doctors and patients gained awareness of both the condition and treatment, GraMedica^®, global orthopedic medical device company and maker of HyProCure^®, experienced rapid growth.

Dr. Graham was determined to improve patient outcomes by providing this revolutionary solution. In order to share his knowledge and expertise with other foot and ankle surgeons, he founded the Graham International Implant Institute^® (GIII^®) in August 2006. The mission of GIII^® is to elevate the standard of care in the arena of Extra-Osseous TaloTarsal Stabilization through education. Since the release of HyProCure^®, many peer-reviewed studies have been published recognizing the proven results of this EOTTS device. Learn more at http://www.gramedica.com/library/.

HyProCure^® is available to patients in over 27 counties. At year end, 2011, more than 16,000 procedures had been performed all around the world. “We are proud to stand behind a product that is truly changing the lives of patients, and we will continue our efforts to educate, create awareness and bring this solution to physicians and patients worldwide,” said Susan Doherty, Director, Education & Physician Resources at GraMedica^®.

Foot and ankle surgeons are invited to learn more about the HyProCure^® implant and procedure at http://www.GraMedica.com, where they can also train online and/or find a live surgical training seminar in their area.

Potential surgical candidates can find out more about the HyProCure^® solution and the devastating effects of talotarsal dislocation at http://www.HyProCure.com. Find a local HyProCure^® specialist through the physician locator at www.HyProCure.com/doctorlocator.php.

Learn more about HyProCure^® and osteo-WEDGE™, GraMedica^®’s latest innovative Bone Locking System at www.GraMedica.com; follow updates on Facebook.com/HyProCure.

Contact:
Susan Doherty, Director, Education & Physician Resources
+1-586-677-9600
sdoherty@grahamiii.com